Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALOTHANE vs ETOMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Induction and maintenance of general anesthesia,Sedation in intensive care (off-label),Status asthmaticus (off-label, due to bronchodilation)
Induction of general anesthesia,Procedural sedation (off-label),Rapid sequence intubation (off-label)
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Halothane is metabolized in the liver primarily by cytochrome P450 2E1 (CYP2E1) to trifluoroacetic acid and bromide ion; reductive metabolism also produces chloride ions and free radicals.
Etomidate is extensively metabolized in the liver via hydrolysis of the ester side chain by hepatic esterases to its principal metabolite, etomidate carboxylic acid. A minor metabolite is formed via N-demethylation. Metabolites are inactive.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Approximately 20-30% bound to plasma proteins, primarily albumin and lipoproteins.
76% bound to albumin.
Volume of distribution at steady state (Vdss) approximately 2-5 L/kg; large Vd indicates extensive tissue distribution, especially to adipose tissue, brain, and muscle.
Vd: 2.5–4.5 L/kg (large, indicating extensive tissue uptake).
100% bioavailable via inhalation (only route of administration). Oral bioavailability not applicable.
IV: 100% (only route used clinically).
No specific dose adjustment required for renal impairment; use with caution due to potential nephrotoxicity from fluoride ions.
No dose adjustment required for renal impairment. Hemodialysis does not alter dosing. Use caution in severe renal failure due to propylene glycol vehicle if prolonged infusion.
Child-Pugh Class A: no adjustment; Child-Pugh Class B and C: avoid use; contraindicated in patients with hepatic impairment or history of halothane-induced hepatotoxicity.
No specific adjustment for Child-Pugh class. However, prolonged effect may occur in severe hepatic impairment; reduce induction dose by 50% and titrate to effect.
Induction: 0.5-2% in oxygen or oxygen-nitrous oxide mixture, gradually increased; Maintenance: 0.3-1.5% as needed. Use lowest effective dose.
Induction: 0.2–0.6 mg/kg IV (max 40 mg). Age >10 years: use adult dosing. Neonates and infants: reduce dose to 0.3 mg/kg due to higher volume of distribution.
Reduce dose by 25-50% due to increased sensitivity and reduced clearance; monitor hemodynamics closely.
Induction: 0.15–0.3 mg/kg IV (50% reduction of adult dose) due to decreased clearance and increased sensitivity. Use lower end of dosing range.
Halothane can cause hepatic necrosis, which may be fatal. Fatalities have occurred in patients with previous halothane exposure. Avoid repeat exposure within 3-6 months.
Etomidate has been associated with mortality in children. It should not be used in children younger than 6 months of age. (This warning is included in the prescribing information based on FDA labeling; specific text may vary.)
Hepatotoxicity (halothane hepatitis), malignant hyperthermia, cardiac arrhythmias (sensitizes myocardium to catecholamines), respiratory depression, hypotension, increased intracranial pressure.
Inhibition of adrenal steroidogenesis (adrenal suppression) due to blockade of 11-beta-hydroxylase, leading to decreased cortisol and aldosterone production; may persist for 12-24 hours after single dose,Myoclonic movements during induction (involuntary muscle contractions),Hypotension and bradycardia (less common than with other induction agents),Venous irritation and pain on injection (may be reduced by using larger veins)
Hypersensitivity to halothane, known or suspected susceptibility to malignant hyperthermia, history of unexplained jaundice or fever after halothane, hepatic dysfunction following previous halothane exposure, pregnancy (relative, especially first trimester).
Hypersensitivity to etomidate,Patients with acute porphyria (may be porphyrinogenic)
No specific food interactions. However, fasting is required before anesthesia to reduce aspiration risk. Alcohol should be avoided for at least 24 hours post-anesthesia due to additive CNS depression.
No specific food interactions are known. Etomidate is administered intravenously and does not have oral bioavailability. However, concurrent use of drugs that affect CYP3A4 (e.g., grapefruit juice) is not clinically significant due to IV route.
Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated with a potential increased risk of congenital malformations based on limited epidemiological data. Second and third trimester use may cause fetal depression and uterine atony; prolonged exposure can lead to neonatal respiratory depression. Avoid use during pregnancy unless clearly needed.
Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a slightly increased risk of congenital malformations, but data are limited. Risks to the fetus should be weighed against the benefits of maternal anesthesia. The drug is not recommended during pregnancy unless clearly needed, especially during organogenesis. In the second and third trimesters, etomidate may cause fetal central nervous system depression and respiratory depression if used near term.
Halothane is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.4. Due to low oral bioavailability, risks to the nursing infant are minimal. However, caution is advised as effects on the infant have not been fully studied. Consider pumping and discarding milk for 24-48 hours after anesthesia to minimize exposure.
It is unknown whether etomidate is excreted in human breast milk. The molecular weight (244.3) suggests potential excretion into milk. The milk-to-plasma ratio (M/P) has not been determined. Due to the short half-life (2–5 hours) and use as a single induction dose, transfer to the infant is likely minimal. However, caution is advised. The American Academy of Pediatrics classifies etomidate as 'compatible' with breastfeeding after a single dose, but data are insufficient for repeated or prolonged use. Infants should be monitored for sedation and respiratory depression.
No specific dose adjustment is recommended, but pregnancy alters pharmacokinetics: increased volume of distribution and decreased protein binding may require higher initial doses to achieve desired anesthetic depth. However, due to increased sensitivity to myocardial depression and uterine relaxation, use the minimum effective dose. Reduce concentration as needed to maintain uterine perfusion and avoid fetal hypoxia.
No specific dose adjustments are recommended for etomidate during pregnancy, but the dose should be individualized to achieve the desired level of anesthesia with the lowest effective dose. Physiologic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect pharmacokinetics, but etomidate is rapidly redistributed and has a short duration of action. The standard induction dose of 0.2–0.6 mg/kg IV is used. Close monitoring of maternal and fetal status is advised. In cesarean section, lower doses may be considered to reduce fetal depression.
Halothane is a volatile halogenated hydrocarbon anesthetic. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias; avoid epinephrine use. Associated with halothane hepatitis (immune-mediated hepatotoxicity), especially with multiple exposures. Malignant hyperthermia trigger; have dantrolene ready. Use with caution in patients with increased intracranial pressure as it can elevate ICP. Use with low fresh gas flows to minimize pollution and cost.
Etomidate is an induction agent of choice in hemodynamically unstable patients due to minimal cardiovascular depression. Adrenal suppression occurs even after a single dose, manifesting as decreased cortisol and aldosterone synthesis via 11β-hydroxylase inhibition. Administer slowly over 30-60 seconds to reduce myoclonus and pain on injection. Use a lower dose (0.2-0.3 mg/kg IV) in elderly or debilitated patients. Etomidate is not recommended for rapid sequence intubation in septic shock due to risk of adrenal insufficiency; consider ketamine as alternative. Prolonged infusion is not advised due to propylene glycol vehicle and adrenal suppression.
This medication will make you unconscious for surgery. You will not feel pain or remember the procedure.,You must fast before anesthesia; do not eat or drink for at least 6-8 hours before surgery.,Tell your anesthesiologist about any liver problems or previous reactions to anesthesia.,Notify your doctor if you have a personal or family history of malignant hyperthermia.,Avoid alcohol for at least 24 hours after anesthesia.,Do not drive or operate machinery for 24 hours after receiving halothane.
You may experience brief involuntary muscle movements during injection, which are usually harmless.,Tell your doctor if you have adrenal gland problems or are taking corticosteroids.,This drug may cause a temporary decrease in your body's ability to produce stress hormones.,Avoid driving or operating machinery until the effects of the medication have completely worn off.,Report any severe pain at the injection site or unusual weakness after the procedure.
"Efonidipine, a dihydropyridine calcium channel blocker, inhibits L-type and T-type calcium channels, leading to vasodilation and reduced myocardial contractility. Halothane, a volatile inhalational anesthetic, depresses myocardial function and sensitizes the myocardium to catecholamines, increasing the risk of arrhythmias. Concurrent use can result in additive negative inotropic effects and profound hypotension, potentially leading to cardiovascular collapse."
"Halothane, a volatile anesthetic, can inhibit the cytochrome P450 enzyme CYP2B6, which is primarily responsible for the metabolism of bupropion, an antidepressant and smoking cessation aid. This inhibition leads to decreased clearance of bupropion, resulting in elevated plasma concentrations that increase the risk of dose-dependent adverse effects such as seizures, anxiety, and insomnia. Clinically, patients may exhibit heightened neuropsychiatric toxicity and reduced seizure threshold, particularly during and after halothane anesthesia."
"Halothane, a volatile halogenated anesthetic, inhibits cytochrome P450 (CYP) isoenzymes, particularly CYP2C19, which is crucial for the hepatic bioactivation of clopidogrel to its active metabolite. Concomitant administration can lead to reduced plasma concentrations of the active thiol metabolite of clopidogrel, diminishing its antiplatelet effect and increasing the risk of thrombotic events such as stent thrombosis or myocardial infarction in patients with coronary artery disease. This interaction is especially significant in patients undergoing surgery where halothane is used for anesthesia while clopidogrel is indicated for recent acute coronary syndrome or percutaneous coronary intervention."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"The combination of Promazine, a phenothiazine antipsychotic with strong alpha-adrenergic blocking activity, and Etomidate, a non-barbiturate hypnotic used for induction of anesthesia, can lead to an increased risk of hypotension due to additive vasodilatory effects. Promazine's alpha-1 receptor antagonism impairs compensatory vasoconstriction, while Etomidate suppresses adrenal cortisol synthesis, potentially blunting the stress response and further reducing hemodynamic stability. Clinically, this interaction may result in profound hypotension, especially in hypovolemic or elderly patients, requiring careful dose titration and monitoring."
"The coadministration of oxazepam, a benzodiazepine that enhances GABA-A receptor activity, with etomidate, a non-barbiturate anesthetic that also potentiates GABA-A receptor function, results in additive central nervous system (CNS) depression. This synergistic interaction can lead to excessive sedation, respiratory depression, hypotension, and prolonged recovery from anesthesia. Patients are at increased risk of apnea, hypoxia, and hemodynamic instability, particularly during induction and maintenance of anesthesia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALOTHANE vs ETOMIDATE, answered by our medical review team.
HALOTHANE is a General Anesthetic that works by Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.. ETOMIDATE is a General Anesthetic that works by Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALOTHANE and ETOMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALOTHANE is: Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.. The standard adult dose of ETOMIDATE is: Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HALOTHANE and ETOMIDATE. The risk or severity of adverse effects can be increased when Etomidate is combined with Halothane. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HALOTHANE is classified as Category C. Halothane is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects, but adequate human studies are lacking. First trimester exposure is associated w. ETOMIDATE is classified as Category C. Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-co. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.